logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10780084 B1

PDFFull Text
Date of Patent:
Sep. 22, 2020

Filed:

Aug. 03, 2017

Antibody-recruiting molecules for the treatment of cancer

Applicants:

Yale University, New Haven, CT (US);

Kleo Pharmaceuticals, Inc., New Haven, CT (US);

Inventors:

David Spiegel, New Haven, CT (US);

H. Marie Loughran, Perkasie, PA (US);

Jeffrey C. Pelletier, Lafayette Hill, PA (US);

Allen B. Reitz, Lansdale, PA (US);

Matthew Ernest Welsch, New Haven, CT (US);

Assignees:

YALE UNIVERSITY, New Haven, CT (US);

KLEO PHARMACEUTICALS, INC., New Haven, CT (US);

Attorneys:

Henry D. Coleman

R. Neil Sudol

Primary Examiner:

Taofiq A Solola

Int. Cl.
CPC ...
A61K 31/454 (2006.01); A61K 45/06 (2006.01); A61P 35/04 (2006.01); A61K 47/55 (2017.01); C07D 261/20 (2006.01); A61P 35/00 (2006.01); C07D 211/26 (2006.01); A61P 35/02 (2006.01); C07D 413/04 (2006.01); C07D 413/14 (2006.01); C07D 211/62 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/454 (2013.01); A61K 45/06 (2013.01); A61K 47/55 (2017.08); A61P 35/00 (2018.01); A61P 35/02 (2018.01); A61P 35/04 (2018.01); C07D 211/26 (2013.01); C07D 211/62 (2013.01); C07D 261/20 (2013.01); C07D 413/04 (2013.01); C07D 413/14 (2013.01); A61K 9/0019 (2013.01);
Abstract

The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic and other cancers where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds bind to the urokinase-type plasminogen activator receptor (uPAR) on the surface of a cancer cell, including a metastatic cancer cell, and consequently recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) against a large number and variety of cancers, thus providing cancer cell death and an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.

Find Patent Forward Citations

Loading…